H.C. Wainwright downgraded Cyclo Therapeutics (CYTH) to Neutral from Buy with a price target of 95c, down from $3, after the company entered into a definitive merger agreement with Rafael Holdings (RFL), which has agreed to acquire the company for 95c per share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTH:
- Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings
- Cyclo Therapeutics reports Q2 net loss approximately $6M
- CYTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cyclo Therapeutics granted patent by European Patent Office
- One new option listing and eighteen option delistings on July 22nd